

---

## Section 1: S-8 (S-8)

Registration No. 333-

---

**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

---

**FORM S-8**  
**REGISTRATION STATEMENT**  
**UNDER**  
**THE SECURITIES ACT OF 1933**

---

**Evolent Health, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of  
incorporation or organization)

**32-0454912**

(I.R.S. Employer  
Identification No.)

**800 N. Glebe Road, Suite 500**  
**Arlington, VA 22203**  
**(571) 389-6000**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

---

**Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan**  
(Full title of the plan)

---

**Frank Williams**  
**Chief Executive Officer**  
**Evolent Health, Inc.**  
**800 N. Glebe Road, Suite 500**  
**Arlington, VA 22203**  
**(571) 389-6000**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

---

*Copies to:*

**William V. Fogg, Esq.**  
**Cravath, Swaine & Moore LLP**  
**Worldwide Plaza**  
**825 Eighth Avenue**  
**New York, New York 10019**  
**(212) 474-1000**

**Jonathan Weinberg**  
**General Counsel**  
**Evolent Health, Inc.**  
**800 N. Glebe Road, Suite 500**  
**Arlington, VA 22203**  
**(571) 389-6000**

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer  Non-accelerated filer  (Do not check if a smaller reporting company)

Smaller reporting company

## CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities to be Registered	Amount to be Registered (1)	Proposed Maximum Offering Price Per Share (2)	Proposed Maximum Aggregate Offering Price (2)	Amount of Registration Fee
Class A Common Stock, \$0.01 par value per share	4,525,000 shares	\$ 22.525	\$ 101,925,625.00	\$ 12,689.74

- (1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of Class A common stock that may become issuable under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, as amended, pursuant to this Registration Statement by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of the registrant's outstanding shares of Class A common stock.
- (2) Estimated solely for the purpose of computing the registration fee pursuant to Rules 457(c) and 457(h) under the Securities Act based on the average of the high and low prices for the Class A common stock as reported on the New York Stock Exchange on June 11, 2018.

## EXPLANATORY STATEMENT

This Registration Statement is filed by Evolent Health, Inc. (the “Company”) pursuant to General Instruction E to Form S-8. The contents of the Registration Statement on Form S-8 previously filed on June 8, 2015 (File No. 333-204785) are incorporated by reference herein and made a part hereof, except as supplemented, amended or superseded by the information set forth below. This Registration Statement on Form S-8 is filed by Evolent Health, Inc. to register an additional 4,525,000 shares of Class A common stock that may become issuable under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, as amended (the “Amended 2015 Plan”). The Amended 2015 Plan has been amended to (i) authorize an additional 4,525,000 shares of Class A common stock for issuance under the Amended 2015 Plan (ii) authorize an additional 4,525,000 shares of Class A common stock that may be delivered pursuant to incentive stock options granted under the Amended 2015 Plan, (iii) provide that the minimum vesting period of 12 months is applicable to all awards granted under the Amended 2015 Plan, except for awards relating to an unrestricted pool of five percent (5%) of the authorized shares of our Class A common stock under the Amended 2015 Plan, subject to any accelerated vesting otherwise permitted by the terms of the Amended 2015 Plan and (iv) provide that dividends and dividend equivalents in respect of any award (including any performance-based award) under the Amended 2015 Plan will only be paid or vested to the extent that the applicable vesting criteria have been satisfied.

### Part II

#### INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

##### Item 6. Indemnification of Directors and Officers.

Section 145 of the Delaware General Corporate Law (the “DGCL”) provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee or agent to the registrant. The DGCL provides that Section 145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise. Our second amended and restated certificate of incorporation provides for indemnification by Evolent Health, Inc. of its directors, and our second amended and restated bylaws provide for the indemnification by Evolent Health, Inc. of its directors and officers, in each case to the fullest extent permitted by the DGCL, subject to certain limitations.

Section 102(b)(7) of the DGCL permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) for unlawful payments of dividends or unlawful stock repurchases, redemptions or other distributions, or (iv) for any transaction from which the director derived an improper personal benefit. Our second amended and restated certificate of incorporation provides for such limitation of liability.

We maintain standard policies of insurance under which coverage is provided (i) to our directors and officers against loss arising from claims made by reason of breach of duty or other wrongful act, and (ii) to Evolent Health, Inc. with respect to payments which may be made by us to such officers and directors pursuant to the above indemnification provision or otherwise as a matter of law.

We have entered into customary indemnification agreements with each of our directors and executive officers. The indemnification agreements provide the executive officers and directors with contractual rights to indemnification and expense reimbursement, to the fullest extent permitted under the DGCL. The indemnification agreements also require Evolent Health, Inc. to advance expenses to its directors and executive officers as incurred in connection with legal proceedings against them for which they may be indemnified and that the rights conferred in the indemnification agreements are not exclusive.



KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Nicholas McGrane, Jonathan Weinberg, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agents full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or either of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

<b>Name</b>	<b>Title</b>	<b>Date</b>
<u>/s/ Frank Williams</u> <b>Frank Williams</b>	Chief Executive Officer and Director (Chief Executive Officer)	June 18, 2018
<u>/s/ Nicholas McGrane</u> <b>Nicholas McGrane</b>	Chief Financial Officer (Chief Financial Officer)	June 18, 2018
<u>/s/ Lydia Stone</u> <b>Lydia Stone</b>	Chief Accounting Officer and Controller (Chief Accounting Officer)	June 18, 2018
<u>/s/ Seth Blackley</u> <b>Seth Blackley</b>	President and Director	June 18, 2018
<u>/s/ Michael A. D'Amato</u> <b>Michael A. D'Amato</b>	Director	June 18, 2018
<u>/s/ M. Bridget Duffy</u> <b>M. Bridget Duffy, MD</b>	Director	June 18, 2018
<u>/s/ David Farner</u> <b>David Farner</b>	Director	June 18, 2018
<u>/s/ Bruce Felt</u> <b>Bruce Felt</b>	Director	June 18, 2018
<u>/s/ Matthew Hobart</u> <b>Matthew Hobart</b>	Director	June 18, 2018
<u>/s/ Diane Holder</u> <b>Diane Holder</b>	Director	June 18, 2018
<u>/s/ Norman Payson</u> <b>Norman Payson, MD</b>	Director	June 18, 2018
<u>/s/ Kenneth Samet</u> <b>Kenneth Samet</b>	Director	June 18, 2018
<u>/s/ Cheryl Scott</u> <b>Cheryl Scott</b>	Director	June 18, 2018

[\(Back To Top\)](#)

## **Section 2: EX-5.1 (EXHIBIT 5.1)**

[Letterhead of]  
Cravath, Swaine & Moore LLP  
[New York Office]

June 18, 2018

Evolut Health, Inc.

Ladies and Gentlemen:

We have acted as counsel for Evolut Health, Inc., a Delaware corporation (the "Company"), in connection with the registration statement on Form S-8 (the "Registration Statement"), filed by the Company with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), relating to the Company's 4,525,000 shares of Class A Common Stock, par value \$0.01 per share (the "Shares"), issuable pursuant to the Evolut Health, Inc. 2015 Omnibus Incentive Compensation Plan (as amended, the "2015 Plan").

In that connection, we have examined originals, or copies certified or otherwise identified to our satisfaction, of such documents, corporate records and other instruments as we have deemed necessary or appropriate for the purposes of this opinion, including, without limitation: (a) the second amended and restated certificate of incorporation of the Company; (b) the second amended and restated by-laws of the Company; (c) certain resolutions adopted by the board of directors of the Company; and (d) the 2015 Plan.

In rendering our opinion, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, conformed or photostatic copies and the authenticity of the originals of such latter documents. As to all questions of fact material to this opinion that have not been independently established, we have relied upon certificates or comparable documents of officers and representatives of the Company.

Based on the foregoing and in reliance thereon, and subject to compliance with applicable state securities laws, we are of opinion that the Shares when, and if, issued pursuant to the terms of the 2015 Plan will be validly issued, fully paid and non-assessable.

We are admitted to practice in the State of New York, and we express no opinion as to matters governed by any laws other than the laws of the State of New York, the General Corporation Law of the State of Delaware and the Federal laws of the United States of America. The reference and limitation to the General Corporation Law of the State of Delaware includes the statutory provisions and all applicable provisions of the Delaware Constitution and reported judicial decisions interpreting these laws.

We hereby consent to the filing of this opinion with the Commission as Exhibit 5.1 to the Registration Statement. In giving this consent, we do not thereby admit that we are included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

Very truly yours,

/s/ Cravath, Swaine & Moore LLP  
Cravath, Swaine & Moore LLP

Evolut Health, Inc.  
800 N. Glebe Road, Suite 500  
Arlington, VA 22203

[\(Back To Top\)](#)

### Section 3: EX-23.1 (EXHIBIT 23.1)

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Evolent Health, Inc. of our report dated March 1, 2018 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in Evolent Health, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2017.

/s/ PricewaterhouseCoopers LLP

McLean, Virginia  
June 18, 2018

[\(Back To Top\)](#)

## **Section 4: EX-23.2 (EXHIBIT 23.2)**

**Exhibit 23.2**

### CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Evolent Health, Inc. of our report dated February 29, 2016 relating to the financial statements of Evolent Health LLC (Predecessor), which appears in Evolent Health, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2017.

/s/ PricewaterhouseCoopers LLP

McLean, Virginia  
June 18, 2018

[\(Back To Top\)](#)

## **Section 5: EX-23.3 (EXHIBIT 23.3)**

**Exhibit 23.3**

### CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Evolent Health, Inc. of our report dated March 2, 2017 relating to the financial statements of Evolent Health LLC (Successor), which appears in Evolent Health, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2017.

/s/ PricewaterhouseCoopers LLP

McLean, Virginia  
June 18, 2018

[\(Back To Top\)](#)